Maria Pasquale Net Worth

The estimated Net Worth of Maria E Pasquale is at least $9.84 Million dollars as of 31 January 2023. Ms. Pasquale owns over 802 units of Incyte stock worth over $4,376,550 and over the last 6 years she sold INCY stock worth over $1,843,716. In addition, she makes $3,623,470 as Executive Vice President and General Counsel at Incyte.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Ms. Pasquale INCY stock SEC Form 4 insiders trading

Maria has made over 28 trades of the Incyte stock since 2019, according to the Form 4 filled with the SEC. Most recently she exercised 802 units of INCY stock worth $59,974 on 31 January 2023.

The largest trade she's ever made was exercising 60,024 units of Incyte stock on 30 January 2023 worth over $4,405,161. On average, Maria trades about 2,261 units every 25 days since 2018. As of 31 January 2023 she still owns at least 69,326 units of Incyte stock.

You can see the complete history of Ms. Pasquale stock trades at the bottom of the page.

Maria Pasquale biography

Maria E. Pasquale is Executive Vice President and General Counsel of the company. Prior to joining Incyte, Ms. Pasquale joined Incyte from Celgene Corporation, a biopharmaceutical company, where for 17 years she held positions of increasing levels of responsibility, including Chief Counsel; Senior Vice President, Legal and Deputy General Counsel and Assistant Corporate Secretary, and, most recently, Executive Vice President and Global Chief Compliance Officer. Prior to her tenure at Celgene, Ms. Pasquale spent a decade supporting pharmaceutical clients as a global patent and litigation attorney at Pennie & Edmonds LLP in New York (now part of Jones Day). Before her career in law, Ms. Pasquale was an Assistant Research Scientist at the Institute for Basic Research and the Cold Spring Harbor Laboratory. Ms. Pasquale holds a J.D. from Brooklyn Law School and a B.S. in biochemistry from the State University of New York at Stony Brook.

What is the salary of Maria Pasquale?

As the Executive Vice President and General Counsel of Incyte, the total compensation of Maria Pasquale at Incyte is $3,623,470. There are 5 executives at Incyte getting paid more, with Herve Hoppenot having the highest compensation of $15,151,200.

How old is Maria Pasquale?

Maria Pasquale is 53, she's been the Executive Vice President and General Counsel of Incyte since 2018. There are 19 older and 5 younger executives at Incyte. The oldest executive at Incyte Corp. is Pamela M. Murphy, 70, who is the VP of Investor Relations & Corp. Communications.

What's Maria Pasquale's mailing address?

Maria's mailing address filed with the SEC is 1801 AUGUSTINE CUT-OFF, , WILMINGTON, DE, 19803.

Insiders trading at Incyte

Over the last 21 years, insiders at Incyte have traded over $114,417,378 worth of Incyte stock and bought 24,211,970 units worth $713,884,116 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B..., and Brothers Life Sciences Capi.... On average, Incyte executives and independent directors trade stock every 14 days with the average trade being worth of $4,355,654. The most recent stock trade was executed by Steven H Stein on 12 August 2024, trading 11,608 units of INCY stock currently worth $703,793.

What does Incyte do?

incyte is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. our vision is to become a leader in the development and delivery of novel drugs for serious unmet medical needs. we have established multiple collaborations with major pharmaceutical companies to support the clinical development and global commercialization of several of our compounds. the incyte corporate headquarters is located in wilmington, delaware, and more than 625 employees comprise our experienced management, discovery, clinical development and commercial teams. our assets, experience and prior success in bringing important new drugs to market put us in a strong position to make a difference by improving the lives of patients and building sustainable value for our shareholders. for more information about incyte, please visit our corporate website at www.incyte.com.

Complete history of Ms. Pasquale stock trades at Incyte

Incyte executives and stock owners

Incyte executives and other stock owners filed with the SEC include:

• Herve Hoppenot,
  Chairman of the Board, President, Chief Executive Officer
• Steven Stein,
  Executive Vice President, Chief Medical Officer
• Wenqing Yao,
  Executive Vice President, Head of Discovery Chemistry
• Barry Flannelly,
  Executive Vice President and General Manager - US
• Christiana Stamoulis,
  Chief Financial Officer, Executive Vice President
• Maria Pasquale,
  Executive Vice President, General Counsel
• Herve Hoppenot,
  Chairman, Pres & CEO
• Paula Swain,
  Executive Vice President - Human Resources
• Christiana Stamoulis,
  Exec. VP & CFO
• Dr. Steven H. Stein,
  Exec. VP & Chief Medical Officer
• Dr. Vijay K. Iyengar M.D.,
  Exec. VP of Global Strategy & Corp. Devel.
• Dr. Barry P. Flannelly M.B.A., MBA, Pharm.D.,
  Exec. VP & GM of North America
• Dr. Barry P. Flannelly M.B.A., Pharm.D., MBA,
  Exec. VP & GM of North America
• Julian Baker,
  Lead Independent Director
• Paul Clancy,
  Independent Director
• Wendy Dixon,
  Independent Director
• Jacqualyn Fouse,
  Independent Director
• Jean-Jacques Bienaime,
  Independent Director
• Paul Friedman,
  Independent Director
• Edmund Harrigan,
  Independent Director
• Michael Booth,
  Vice President - Investor Relations
• Katherine High,
  Independent Director
• Vijay Iyengar,
  Executive Vice President, Global Strategy and Corporate Development
• Dashyant Dhanak,
  Executive Vice President, Chief Scientific Officer
• Thomas Tray,
  VP of Fin., Chief Accounting Officer & Controller
• Pamela M. Murphy,
  VP of Investor Relations & Corp. Communications
• Maria E. Pasquale,
  Exec. VP & Gen. Counsel
• Christine Chiou,
  Head of Investor Relations
• Dr. Dashyant Dhanak Ph.D.,
  Exec. VP & Chief Scientific Officer
• Michael James Morrissey,
  Exec. VP & Head of Global Technical Operations
• Reid M Huber,
  EVP, Chief Scientific Officer
• Julian14159, L.P.667, L.P.B...,
  
• David W Gryska,
  Executive Vice President, CFO
• Paul Trower,
  Principal Accounting Officer
• Julianbaker Felixbaker Bros...,
  
• Eric H. Siegel,
  EVP, General Counsel
• Paul A Brooke,
  Director
• Matteo Trotta,
  EVP, GM, Dermatology US
• Bros. Advisors Lp14159, L.P...,
  
• Bros. Advisors Lp Baker Bro...,
  
• Bros. Capital (Gp), Llcbake...,
  
• Schutter Richard U De,
  Director
• Barry A Ariko,
  Director
• Foundation Inc Damial,
  10% owner
• Daniel R Tisch,
  10% owner
• Julian Baker,
  Director
• Biotech Capital Ii Gp Llcba...,
  
• James M Daly,
  Exec. VP & Chief Comm. Officer
• Brothers Life Sciences Capi...,
  
• Laurent Chardonnet,
  VP Finance and Treasurer
• John A Keller,
  Exec VP & Chief Bus Officer
• Jon S Saxe,
  Director
• Biotech Capital (Gp), Llcba...,
  
• / Tisch Capital (Gp), Llcba...,
  
• Brothers Life Sciences Capi...,
  
• John F Niblack,
  Director
• Biotech Capital (Gp), Llcba...,
  
• Fred B Craves,
  Director
• Biotech Capital Gp Llcbaker...,
  
• David C Hastings,
  Exec VP & CFO
• Patricia A Schreck,
  EVP and General Counsel
• / Tisch Capital (Gp), Llcba...,
  
• Richard S Levy,
  EVP, Chief Drug Dev&Medical Of
• Biotech Capital (Gp), Llcba...,
  
• Scott W Hurley,
  
• Capital (Gp), Llcbaker Feli...,
  
• Matthew Emmens,
  Director
• / Tisch Capital (Gp), Llcba...,
  
• Capital (Gp), Llcbaker Juli...,
  
• Steven M. Friedman,
  EVP, Biology & Preclinical Dev
• Bros. Capital (Gp), Llcbake...,
  
• Julianbaker Felixbaker Bros...,
  
• James S Tisch,
  10% owner
• Bros. Capital (Gp), Llcbake...,
  
• Brian W Metcalf,
  
• Andrew H Tisch,
  10% owner
• Michael James Morrissey,
  EVP, Head of Tech. Operations
• Thomas J Tisch,
  10% owner
• Roy A Whitfield,
  Director
• Capital (Gp), Llcbaker Juli...,
  
• Biotech Capital Ii Gp Llcba...,
  
• Brothers Life Sciences Capi...,
  
• Bonnie J Tisch,
  10% owner
• Bros. Advisors Lp667, L.P.B...,
  
• Jonathan Elliott Dickinson,
  EVP, General Manager, Europe
• Bros. Advisors Lp Baker Bro...,
  
• Thomas Tray,
  Principal Accounting Officer
• Otis W Brawley,
  Director
• Bros. Advisors Lp667, L.P.B...,
  
• Pablo J Cagnoni,
  President, R&D
• Susanne Schaffert,
  Director
• Sheila A. Denton,
  EVP & General Counsel